Related Experiment Video
Updated: Jun 30, 2025

04:08
Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
Published on: January 18, 2021
2.8K
ASSESSMENT OF RAT BRAIN MORPHOFUNCTIONAL STATE IN A PARKINSON'S MODEL: INFLUENCE OF THERAPEUTIC AGENTS OF ANIMAL AND
M Danielyan1, K Nebogova1, Z Avetisyan1
1Orbeli Institute of Physiology NAS RA, Yerevan, Armenia.
Georgian Medical News
|March 19, 2024
Summary
Bacterial melanin and synoestrol show promise in protecting brain cells in Parkinson's disease models. These agents may help restore normal cell structure and metabolic activity in affected brain regions.
Area of Science:
- Neuroscience
- Neurodegenerative Diseases
- Pharmacology
Background:
- Neurodegenerative diseases like Parkinson's disease (PD) often involve antinociceptive centers, leading to intractable pain.
- The periaqueductal gray matter (PAG) and nucleus raphe magnus (NRM) are key antinociceptive structures implicated in PD neurodegeneration.
Purpose of the Study:
- To investigate the neuroprotective potential of bacterial melanin and synoestrol.
- To examine their effects on PAG and NRM neurons in a rotenone-induced rat model of PD.
Main Methods:
- Induction of a PD model using rotenone intoxication in rats.
- Morphological and biochemical analysis of PAG and NRM neurons.
- Assessment of acid phosphatase activity in neuronal cytoplasm.
Main Results:
- Rotenone intoxication caused significant morphological changes and disrupted acid phosphatase activity in PAG and NRM neurons.
- Bacterial melanin and synoestrol treatment preserved neuronal morphology and normalized cell size and shape.
- Phosphatase activity increased in treated neurons, indicating metabolic activation.
Conclusions:
- Bacterial melanin and synoestrol demonstrate potential neuroprotective effects on PAG and NRM neurons in a PD model.
- These agents may counteract rotenone-induced metabolic dysfunction in antinociceptive pathways.
- Further research is warranted to explore their therapeutic application in Parkinson's disease treatment.

